TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9508174
Drug: i.t. methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.t. methotrexate (MTX) and cranial radiation therapy (CRT) (regimen A, n = 317)
Study: 9419751
Drug: DHEA infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA infusion (1 mg/hour for 17 hours)
Study: 1915209
Drug: Caffeine (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3.3 mg/kg, equivalent to 2 to 3 cups of coffee)
Study: 8420868
Drug: Misonidazole combined
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misonidazole combined with radiation therapy
Study: 8420868
Drug: Cranial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial treatment responders
Study: 321177
Drug: Naproxen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (300 or 600 mg)
Study: 321177
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (275 mg)
Study: 31736077
Drug: Morus nigra
Normalized name: MORUS NIGRA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morus nigra L. (MN) leaf powder 250 mg for 60 days
Study: 31736077
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) 1 mg estradiol for 60 days
Study: 25586298
Drug: ropinirole prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropinirole prolonged release (PR) administered for 24 weeks as adjunctive to levodopa
Study: 30589922
Drug: Dexamethasone implant
Normalized name: dexamethasone Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone implant after switching from aflibercept
Study: 25695576
Drug: Perioperative smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative smoking cessation intervention (brief counseling, brochures, referral to quitline, 6-week transdermal nicotine replacement)
Study: 21525768
Drug: Synbiotics (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics (1 g of Bifidobacterium breve strain Yakult three times a day and 5.5 g of GOS once a day for one year)
Study: 17892374
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg intravenously once yearly
Study: 16490030
Drug: Aggressive diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive diabetes mellitus treatment and good glycemic control
Study: 11228790
Drug: Anxiolytic premedication
Normalized name: ANXIOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiolytic premedication (midazolam 7.5 mg, midazolam 15 mg, diazepam 15 mg)
Study: 8044953
Drug: Intravenous pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pentoxifylline (200 mg over 2 hours BID) with intensive vascular training
Study: 8044953
Drug: Intravenous prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prostaglandin E1 (40 micrograms over 2 hours BID) with intensive vascular training
Study: 30755171
Drug: Modified full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified full enteral nutrition (standard full EN in conjunction with prokinetic drug)
Study: 25163498
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of roasted flaxseed powder for 3 months
Study: 23095069
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral health care (POHC) treatment by dental hygienists (n = 21)
Study: 19380445
Drug: PCI(10) and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI(10) and PCI(20) - combination of CP-751,871 (10 to 20 mg/kg), paclitaxel (200 mg/m²), and carboplatin (AUC 6) every 3 weeks for up to six cycles.
Study: 7562288
Drug: Amoxicillin prophylaxis
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin prophylaxis
Study: 11965280
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation with measles vaccine
Study: 2219758
Drug: Aspirin with
Normalized name: Bayer Aspirin with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin with dipyridamol
Study: 28423174
Drug: Propranolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (2 mg/kg/d) for 16 weeks
Study: 28423174
Drug: Steroid (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid (2 mg/kg/d) for 16 weeks
Study: 15579519
Drug: Higher hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher hemoglobin targets (> 130 g/L)
Study: 15579519
Drug: Lower hemoglobin
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower hemoglobin targets (< 120 g/L)
Study: 11954942
Drug: Quinapril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril treatment
Study: 11179530
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no quinapril treatment)
Study: 9751014
Drug: End-of-treatment HCV
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-of-treatment HCV RNA response
Study: 1884902
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) treatment for a mean of 13.8 months
Study: 1884902
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) treatment
Study: 30958508
Drug: Rivaroxaban (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (15 mg per day)
Study: 22883004
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of valproic acid (VPA) and lamotrigine (LTG)
Study: 20417262
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13) and 7-valent pneumococcal conjugate vaccine (PCV7)
Study: 14694970
Drug: Intracervical PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical PGE2 (dinoprostone 0.5 mg) by gel (n = 66)
Study: 14694970
Drug: Intravaginal PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravaginal PGE2 (dinoprostone 10 mg) by pessary (n = 49)
Study: 14694970
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (gel and pessary)
Study: 9335389
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2-g treatment group
Study: 9335389
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (quadruple sequential induction therapy)
Study: 8254147
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and Amitriptyline
Study: 2871486
Drug: Control immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control immunosuppressive therapy (azathioprine and prednisone, with or without antilymphocyte globulin)
Study: 30129417
Drug: Topical simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical simvastatin 1% topical solution
Study: 30129417
Drug: Oral simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral simvastatin 20mg/day
Study: 27665525
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (proton pump inhibitor, amoxicillin 1000mg, clarithromycin 500mg or metronidazole 400mg, given twice daily for 7-14 days)
Study: 27665525
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (PPI twice daily for 10 days, amoxicillin 1000mg twice daily for the first 5 days, followed by clarithromycin 500mg and metronidazole 400mg twice daily for the subsequent 5 days)
Study: 22578530
Drug: Brief Motivational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Motivational Intervention for at-risk drinking (BMI-ETOH) among Hispanics with drug dependence
Study: 15302787
Drug: High-dose sirolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sirolimus (24 mg loading dose, 2 mg/d for 7 days)
Study: 15302787
Drug: Usual-dose sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Usual-dose sirolimus (8 mg loading dose, 2 mg/d for 7 days)
Study: 8123267
Drug: Thiopental sodium
Normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopental sodium 4 mg/kg i.v., followed by 0.5% to 1.5% enflurane and 67% N2O in O2 (Group 1)
Study: 8123267
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg i.v., followed by 0.5% to 1.5% enflurane and 67% N2O in O2 (Group 2)
Study: 8123267
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg i.v., followed by propofol 50 to 160 micrograms/kg/min i.v. and 67% N2O in O2 (Group 3)
Study: 3322358
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg, three times daily for 6 weeks
Study: 31115667
Drug: Supervised low-intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised low-intensity cycling for 20 minutes during chemotherapy infusion
Study: 31115667
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care during chemotherapy infusion
Study: 26600017
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum magnesium (Mg) increase of 0.1 mmol/L
Study: 26600017
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum magnesium (Mg) levels over time
Study: 23329358
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy alone
Study: 23329358
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with total body irradiation
Study: 18345709
Drug: Recombinant factor
Normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant factor VIIa (270 microg/kg dose)
Study: 3663564
Drug: oral nadolol
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral nadolol 20 mg once daily
Study: 3663564
Drug: topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical timolol 0.25% twice daily
Study: 16146905
Drug: Complete multivessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete multivessel treatment
Study: 16146905
Drug: Culprit lesion
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culprit lesion treatment only
Study: 8422661
Drug: Selegiline 5
Normalized name: selegiline 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline 5 mg daily
Study: 8422661
Drug: Selegiline 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline 10 mg daily
Study: 9159721
Drug: Selegiline 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline 20 mg weekly (10 mg x 2)
Study: 9159721
Drug: Selegiline 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline 10 mg weekly
Study: 26056856
Drug: Individualised lower
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised lower limb progressive resistance training programme (twice a week for 12 weeks)
Study: 20947887
Drug: LV5FU2-CDDP as
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LV5FU2-CDDP as first-line treatment
Study: 12577231
Drug: Gemcitabine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine as first-line treatment
Study: 17767800
Drug: Isoflavones (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones (50 mg of daidzein and genistein)
Study: 12651635
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 30 mg/kg
Study: 8857512
Drug: High PNG
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High PNG diet (1.52 mg/d of vitamin B-6, 27% PNG)
Study: 8857512
Drug: Low PNG
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low PNG diet (1.44 mg/d of vitamin B-6, 9% PNG)
Study: 1509190
Drug: Almitrine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (100 mg per day)
Study: 6476299
Drug: Buprenorphin sublingual
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphin sublingual (0.4 mg.)
Study: 6476299
Drug: Pentazocin i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocin i.m. (30 mg.)
Study: 29937430
Drug: sotagliflozin 200
Normalized name: sotagliflozin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotagliflozin 200 mg
Study: 24983260
Drug: Heparin flushing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin flushing protocol
Study: 22128082
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous cyclophosphamide (ivCY)
Study: 21284283
Drug: CT gel
Normalized name: PROSOURCE GELATEIN PLUS LIME W/MCT GEL,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT gel (clindamycin phosphate 7.2% - tretinoin 0.025%) + BPO wash 4%
Study: 21284283
Drug: CT gel
Normalized name: PROSOURCE GELATEIN PLUS LIME W/MCT GEL,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT gel (clindamycin phosphate 7.2% - tretinoin 0.025%) + SFC (nonmedicated soap-free cleanser)
Study: 17272314
Drug: Glucose-added bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-added bicarbonate solution (90 mg/dl)
Study: 17272314
Drug: Glucose-free bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-free bicarbonate solution
Study: 15121352
Drug: Antipsychotic continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic continuation
Study: 15121352
Drug: Taper to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper to placebo
Study: 3192904
Drug: Endotelon (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotelon (4 tablets of 50 mg per day for five weeks)
Study: 31773485
Drug: Zinc glycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc glycine chelate (ZnG) at 90 mg Zn/kg
Study: 30213583
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid treatment for 8 weeks
Study: 18450903
Drug: Needle-free powder
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-free powder lidocaine delivery system (0.5 mg of lidocaine)
Study: 21346100
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (3 mg caffeine/kg body weight)
Study: 19596139
Drug: CA-125 >35
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA-125 >35 U/ml
Study: 2793338
Drug: Shift in
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shift in treatment
Study: 21993153
Drug: Brief transdiagnostic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief transdiagnostic internet treatment (Wellbeing Program)
Study: 20186639
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (self-monitoring daily pedometer step count)
Study: 2894904
Drug: Terfenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (60 mg b.i.d.)
Study: 11325074
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (benazepril at a dose of 2.5 mg daily)
Study: 11325074
Drug: Alphabeta blocker
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alphabeta blocker (arotinolol at a dose of 20 mg daily)
Study: 7956637
Drug: Normal urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal urinary albumin excretion (UAE)
Study: 3791141
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with chemotherapy and intensive meningeal radiotherapy (vincristine, actinomycin D, cyclophosphamide, Adriamycin, 4000 to 5500 rad radiation therapy, intrathecal drugs)
Study: 3791141
Drug: Preintensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preintensive treatment with chemotherapy and nonintensive meningeal radiotherapy (vincristine, actinomycin D, 4000 to 5500 rad radiation therapy)
Study: 3791141
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (within group analysis)
Study: 24022862
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg daily for 7 days)
Study: 10410527
Drug: Aquatic exercises
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic exercises (frequency: once a week, twice a week, or 3 or more times a week)
Study: 7772012
Drug: medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medroxyprogesterone acetate 2.5 mg daily
Study: 7772012
Drug: medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medroxyprogesterone acetate 5 mg daily
Study: 7772012
Drug: medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medroxyprogesterone acetate 10 mg daily
Study: 7772012
Drug: medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medroxyprogesterone acetate 2.5 mg, 5 mg, or 10 mg daily
Study: 7772012
Drug: medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medroxyprogesterone acetate 5 mg and 10 mg
Study: 2149046
Drug: Teicoplanin as
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin as first-line treatment
Study: 2149046
Drug: Teicoplanin as
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin as second-line therapy
Study: 23537687
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (solifenacin plus tamsulosin OCAS)
Study: 19274516
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of three disease-modifying anti-rheumatic drugs (DMARDs)
Study: 19274516
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of three DMARDs
Study: 16679098
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (160 subjects receiving treatment)
Study: 16679098
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (short duration <3 years)
Study: 16679098
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (long duration 3 to 9 years)
Study: 16679098
Drug: Non-receiving ACE
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-receiving ACE inhibitors (rest of study population)
Study: 15599144
Drug: Oxygen therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy, CPAP, Bilevel-PAP
Study: 16161718
Drug: Double versus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double versus triple antiretroviral therapy
Study: 11079534
Drug: Citicoline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (500 mg/day) for 6 weeks
Study: 11079534
Drug: Citicoline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (500 mg/day)
Study: 27686226
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg mirabegron once daily
Study: 27686226
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg imidafenacin twice daily
Study: 22853865
Drug: Fesoterodine SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine SR 4 mg
Study: 22853865
Drug: Fesoterodine SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine SR 8 mg
Study: 20164809
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (N3) - 2000 mg eicosapentaenoic acid and 400 mg docosahexaenoic acid
Study: 20164809
Drug: Vitamin-mineral complex
Normalized name: vitamin B complex
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin-mineral complex (VM) - vitamins C (2000 mg), E (800 IU), A (3000 IU), selenium (200 microg)
Study: 20164809
Drug: Vitamin-mineral complex
Normalized name: vitamin B complex
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin-mineral complex and n-3 fatty acid combination (VN3)
Study: 17914135
Drug: Low vitamin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vitamin D stores (18 ng/ml)